Ganglioside G_D2 Polyclonal Antibody

Territorial Availability: Available through Bertin Technologies only in France

• Correlated keywords
  • Nacetylgalactosamine UDPGalNAc ?1,4 Nacetylgalactosaminyltransferase G D2 M2 M1 A1 D1 epithelialtomesenchymal Antiganglioside GD2positive EL4 IMR32
• Product Overview:
  Ganglioside GD2 (Item No. 25487) is a glycosphingolipid that contains two sialic acid residues linked to an inner galactose unit. It is produced by the transfer of N-acetylgalactosamine (GalNAc; Item No. 31728) from UDP-GalNAc to the precursor ganglioside GD3(Item No. 17481) by ?-1,4-N-acetylgalactosaminyltransferase 1 (?4GalNAcT1), also known as ganglioside GM2/GD2 synthase, and can be galactosylated to ganglioside GD1b (Item No. 19569) by ?-1,3-galactosyltransferase 4 (?3GalT4), also known as ganglioside GM1/GA1/GD1 synthase.{58355,58356} Ganglioside GD2 is frequently expressed on the plasma membrane of tumor cells of neuroectodermal origin, including neuroblastomas, as well as bone and soft tissue sarcomas, melanoma, and small cell lung cancer, and is absent or weakly expressed in non-cancerous tissues.{37627,58357} It is induced by expression of the epithelial-to-mesenchymal transition (EMT) inducers Twist and Snail in oncogenic human mammary epithelial cells.{58358} Anti-ganglioside GD2 monoclonal antibodies reduce the viability of GD2-positive EL-4 mouse lymphoma, IMR-32 human neuroblastoma, and mS human melanoma cells, inducing features of both apoptosis and necrosis.{58357} Ganglioside GD2 has been found in more than 90% of neuroblastoma tissue samples, and plasma levels of soluble ganglioside GD2 are associated with tumor progression in patients with neuroblastoma.{58359} Formulations containing chimeric anti-ganglioside GD2 monoclonal antibodies have been used in the treatment of neuroblastoma in children. Ganglioside GD2 Polyclonal Antibody can be used for ELISA and TLC immunoblotting applications. [Matreya, LLC. Catalog No. 1963]